KLRB1 and Miyoshi myopathy: Among these, we selected KLRB1 for further investigation due to two key reasons: 1) KLRB1 encodes the inhibitory receptor CD161, representing a promising therapeutic target; and 2) its expression was notably higher in RRMM, indicating a potentially critical role in advanced stages of MM (Figure 2C).